Results from the Phase 2 Clinical Trial of Serlopitant to Treat Pruritus with Psoriasis to be Presented on March 2, 2019
REDWOOD CITY, Calif., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that an abstract has been accepted for oral presentation at the Late-Breaking Research Program during the 2019 Annual Meeting in Washington, D.C.
The abstract, “Serlopitant Reduced Pruritus Associated with Psoriasis in Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial” will be presented as part of Late Breaking Research: Clinical Trials on Saturday, March 2between 1:00 p.m. and 4:00 p.m. in Ballroom A.
In addition, a second abstract, “Improvement of Itch and Pain in Patients with Prurigo Nodularis Treated with Serlopitant: Secondary analysis of Phase 2 Clinical Trial” was accepted as an oral presentation and online e-poster. Presentations will be held on Friday, March 1 and Saturday, March 2.
Serlopitant is a once-daily oral NK1 receptor antagonist being developed for the treatment of pruritus, or itch, associated with various conditions such as prurigo nodularis, psoriasis and chronic pruritus of unknown origin. Menlo has completed three positive Phase 2 clinical trials with serlopitant showing a statistically significant reduction in pruritus compared to placebo. Serlopitant has been evaluated in over 1,600 patients and has been shown to be well-tolerated, including in patients who have received treatment for up to one year. Serlopitant is an investigational drug that is not currently approved for use in any indication in any country.
About Menlo Therapeutics
Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus. The Company’s clinical development program for serlopitant includes two ongoing Phase 3 clinical trials for the treatment of pruritus associated with prurigo nodularis, a planned Phase 3 program for the treatment of pruritus associated with psoriasis, and a Phase 2 clinical trial for the treatment of chronic pruritus of unknown origin.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Menlo Therapeutics, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including, but not limited to, statements regarding expectations about the Company’s ability to develop and advance product candidates into and successfully complete clinical trials within the anticipated timeframe and to gain regulatory approval to market its product candidates. Such forward-looking statements involve substantial risk and uncertainties that could cause Menlo Therapeutics’ development program for serlopitant, future results, achievements or performance to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties are described in greater detail in Menlo Therapeutics’ Annual Report on Form 10-K filed on March 28, 2018 and its Quarterly Report on Form 10-Q filed on November 7, 2018, as well as any reports that it may file with the SEC in the future, may cause Menlo Therapeutics’ actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Menlo Therapeutics undertakes no obligation to update or revise any forward-looking statements.
Media Contact: email@example.com
Investor Contact: firstname.lastname@example.org
Source: Menlo Therapeutics Inc.